We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Dermatology

Enfortumab Vedotin-Induced Cutaneous Toxicity: A Marker of Improved Survival in Advanced Urothelial Carcinoma

MedXY Editorial Team•Aug 7, 2026•Dermatology
survivalAntibody-drug conjugateenfortumab vedotin尿路上皮がんCutaneous adverse events

Highlight

This multi-institutional retrospective study identifies that cutaneous adverse events (cAEs) specifically induced by enfortumab vedotin (EV) in locally advanced or metastatic urothelial carcinoma patients are common and independently associated with significantly improved progression-free survival (PFS) and overall survival (OS). Notably, early-onset and even high-grade EV-related skin toxicities correlate with favorable clinical outcomes. Distinguishing EV-induced cAEs from other causes is crucial for optimal management and prognostication.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Evolving Epidemiology and Survival Trends in Myeloproliferative Neoplasms: Insights from SEER 2000-2021Analysis of SEER data from 2000-2021 reveals incidence, survival trends, and demographic disparities in US patients with myeloproliferative neoplasms, highlighting improved outcomes particularly in primary myelofibrosis and areas for furtheSep 13, 2026Incidence, Survival, and Symptomatology of Recurrence in Vulvar Cancer: Insights from Population-Based Cohort Studies and Contemporary EvidenceVulvar cancer exhibits significant recurrence rates, predominantly local, with survival declining sharply after recurrence. Awareness of recurrence-associated symptoms enhances early detection. Surgery remains pivotal in management, with frSep 12, 2026Charcot Neuro-Osteoarthropathy in Diabetes: High Risk of Hospitalization, Amputation, and Mortality Revealed by Regional Cohort StudyCharcot neuro-osteoarthropathy (CNO) in people with diabetes is linked to frequent emergency hospitalizations, substantial risk of limb amputation, and reduced survival, highlighting urgent need for intensified multidisciplinary care.Sep 5, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Daratumumab-VCd Combination Significantly Improves Survival in Newly Diagnosed AL Amyloidosis: Insights from the ANDROMEDA Trial
The ANDROMEDA phase 3 trial demonstrates that adding subcutaneous daratumumab to VCd therapy markedly improves hematologic and organ responses, leading to better progression-free and overall survival in newly diagnosed AL amyloidosis patien
Sep 3, 2026
Trends in Incidence, Mortality, and Survival of Endometrial, Ovarian, and Cervical Cancers in Young Nordic Women: Insights from 40 Years of Registry DataThis article analyzes 40-year trends in incidence, mortality, and survival of endometrial, ovarian, and cervical cancers among Nordic women aged 0-49, highlighting evolving epidemiology and implications for age-specific prevention.Aug 22, 2026
Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma: Promising Efficacy Across HER2 Expression LevelsThis phase II trial demonstrates significant antitumor activity of trastuzumab rezetecan in both HER2-high and HER2-low advanced salivary gland carcinoma with a manageable safety profile, offering new hope for this challenging malignancy.Aug 14, 2026